Baystreet Staff - Tuesday, January 3, 2023 Marvel Biosciences Corp 11:31 AM EST - Marvel Biosciences Corp : Announces it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.13. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=MRVL%3ACA&qmodStoryID=8556479051447607